#Nectin4
NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.10.07.757381v1
October 9, 2026 at 7:00 PM
NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer https://www.biorxiv.org/content/10.64898/2026.10.07.757381v1
October 9, 2026 at 4:47 PM
NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer https://www.biorxiv.org/content/10.64898/2026.10.07.757381v1
October 9, 2026 at 4:47 PM
VHHNectin4 #CART cells are engineered for precision.
They expand CD4+ & memory T cells, secrete cytokines & kill Nectin4+ #BladderCancer cells without affecting Nectin4 negative cells, supporting translational promise. #medsky #Oncology
#BIOI #OpenAccess: doi.org/10.15212/bio...
September 21, 2026 at 12:16 PM
Could NECTIN4 localization—and not just expression—help us identify which patients are most likely to benefit from enfortumab vedotin?

aacrjournals.org/clincancerre...

Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting eV Response
September 11, 2026 at 11:07 AM
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!

@ptarantinomd.bsky.soci
al @markuseckstein3.bsky.social
December 11, 2024 at 9:12 AM
Online now: Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer
Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer
He et al. develop NECTIN4-ICG, a Nectin4-targeted fluorescence imaging probe for bladder cancer. In preclinical models and clinical trials, NECTIN4-ICG demonstrates high diagnostic accuracy and improves tumor margin detection compared to conventional white light cystoscopy, enhancing real-time visualization and surgical precision during transurethral resection.
dlvr.it
May 15, 2026 at 12:27 PM
The Triple meeting is coming up this week in Barcelona. Second big oncology meeting in a row after #ESMO24. Some updates we’ll be following:

$RVMD KRAS
$IDYA MAT2A
$TYRA FGFR3
$ERAS BRAF/CRAF
Nested RAF/MEK glue
Aktis Nectin4

#BioSky
October 21, 2024 at 8:11 PM
A paper using RRID:AB_2923704 from @proteintech.bsky.social was just published. Thanks for making your methods matter! #OpenResearch #RRID #methodsmatter
Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer
Read the full paper: Nectin4-targeted molecular imaging for precise endoscopic diagnosis and image-guided surgery in bladder cancer
doi.org
May 28, 2026 at 7:00 AM
The authors included RRIDs in their paper! We value the author's support of reproducibility. #methodsmatter #OpenScience #RRID
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
doi.org
November 25, 2025 at 8:00 AM
RRIDs were included in this Cancer Immunology, Immunotherapy paper. Thanks for making your methods matter! #reproducibility #STMpublishing #reproducibility
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors
doi.org
May 29, 2025 at 7:01 AM
We thank @insight.jci.org for highlighting our study on the cover of the current issue. Discover how #Nectin4 plays a crucial role in #PancreaticCancer and its potential implications for treatment: insight.jci.org/articles/vie...
January 23, 2026 at 5:26 PM
🔬 Importance
9MW2821 is paving the way for Nectin4-targeted therapies beyond urothelial cancers, offering hope for hard-to-treat malignancies. With pivotal trials underway (NCT06196736, NCT06592326, etc.), this ADC could redefine treatment paradigms!

#Onco404 #Cancer #Kanser #MedSky #OncSky
April 30, 2025 at 7:15 PM
The first-in-human study of 9MW2821, a next-gen Nectin4-targeted #ADC, shows promising efficacy in patients with advanced solid tumors who have failed prior therapies.

@myesmo.bsky.social

#Onco404 #Cancer #Kanser #OncSky #Nectin4 #BreastCancer #CervicalCancer #UrothelialCancer #EsophagealCancer
April 30, 2025 at 7:15 PM
Feed: "Nature Communications"
By: Jonathan Chou
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Enfortumab vedotin (EV), an antibody-drug conjugate that targets NECTIN4, has become the new standard of care treatment for patients with advanced bladder cancer, which is also known as urothelial carcinoma (UC). Although EV has proven to be very effective both as monotherapy and in combination with immune checkpoint inhibitors, patients unfortunately develop resistance to EV after about 1 year, which calls for the need to develop new treatment options. In this study, we developed a NECTIN4-targeting chimeric antigen receptor (CAR) T cell, and showed that it was highly effective against bladder cancer cells expressing NECTIN4. We previously found that patient tumors ranged from negative to very high levels of NECTIN4. We showed that cells with higher. NECTIN4 levels were more easily targeted by the CAR T cell. Interestingly, stimulating the PPARγ pathway using small molecules like rosiglitazone (an old diabetes drug) was effective at increasing NECTIN4 expression, particularly in UC cells with lower NECTIN4 levels. This translated into enhanced NECTIN4-CAR T killing in vitro and in mouse tumor xenografts. Moreover, we found that NECTIN4 is largely retained on tumors after patients become resistant to EV, and we developed EV-resistant cell lines to study this. Importantly, NECTIN4-CAR T cells remained effective even against these EV-resistant cancer cells. Together, our findings demonstrate that NECTIN4-CAR T cells are effective, whose activity can be further enhanced by repurposing a diabetes drug, rosiglitazone, to induce NECTIN4. Our findings may pave the way to new therapeutic approaches for bladder cancer patients in the future.
www.nature.com
September 11, 2025 at 7:20 PM
Feed: "Newswise: Latest News"
By: University of California, San Francisco (UCSF) on Wednesday, September 10, 2025
Repurposing a Diabetes Medication to Prime CAR T Cancer Targets
To improve treatment rates for these patients, UCSF researchers designed a CAR T cell therapy and combined it with an older class of diabetes drugs called thiazolidinediones, to enhance NECTIN4 expression and make tumor cells more susceptible to NECTIN4-CAR T therapy.
www.newswise.com
September 10, 2025 at 12:52 PM
#CCG25 Using this to stratify patients leads to strong (>60%) response. Validation (retrospective) in Hartwig Medical Database cohort. Also found in IMvigor210 cohort. NECTIN4 amp patients do not respond. Combined biomarker to now stratify.
March 21, 2025 at 9:31 AM
Fantastic discussion @apolo_andrea @theNCI for past/present/future of nectin4. EV pembro success in #bladdercancer also sets up a new world of challenges for resistance & sequencing approaches. @asco #ASCO26 @oncoalert @urotoday
May 29, 2026 at 10:47 PM
@IyerGopa @MSKCancerCenter with phase 1 #NEXUS01 of nectin4 delivering topoisomerase inhibitor — ligand is still relevant for some EV-pembro refectory #bladdercancer w responses.
@asco #ASCO26 @oncoalert @urotoday
May 29, 2026 at 10:23 PM
🚀 Zacks Small Cap Research - APVO: Focusing on Three Key Areas of Development
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-apvo-focusing-on-three-key-areas-of-development/
#AptevoTh
e#AptevoTherapeuticsp#APVOi#Mipletamig##RAINIER##APVO451##Nectin4d#PDL1r#Radiopharmaceu
August 24, 2026 at 5:05 PM